SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 9,885.41 |
| Enterprise Value ($M) | 10,753.39 |
| Book Value ($M) | 3,405.26 |
| Book Value / Share | 15.32 |
| Price / Book | 2.90 |
| NCAV ($M) | -349.60 |
| NCAV / Share | -1.57 |
| Price / NCAV | -28.28 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.02 |
| Return on Assets (ROA) | 0.01 |
| Return on Equity (ROE) | 0.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.46 |
| Current Ratio | 1.77 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,829.78 |
| Assets | 5,584.64 |
| Liabilities | 2,179.38 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 1,965.31 |
| Operating Income | 453.65 |
| Net Income | 341.30 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 459.45 |
| Cash from Investing | -87.66 |
| Cash from Financing | -433.83 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Massachusetts Financial Services Co /ma/ | 10.50 | -0.26 | |
| 13G/A | BlackRock Inc. | 12.00 | -12.67 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 317,094 | 1,421,700 | 22.30 | |
| 141,519 | 1,213,890 | 11.66 | |
| 43,047 | 1,291,089 | 3.33 | |
| 75,690 | 1,212,217 | 6.24 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PBH – Prestige Consumer Healthcare Inc. | PFE – Pfizer Inc. |
| PRGO – Perrigo Company plc | RCUS – Arcus Biosciences, Inc. |
| USNA – USANA Health Sciences, Inc. |
Financial data and stock pages provided by
Fintel.io